摘要
为了比较诺维本(NVB)和健择(GEM)与顺铂(DDP)联合化疗治疗晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的疗效及毒副反应,选择62例不能手术的晚期NSCLC患者,随机分为NP方案(NVB+DDP)治疗组(NP组)及GP方案(GEM+DDP)治疗组(GP组),观察其疗效和毒副反应。结果NP组和GP组有效率分别为46.9%(15/32)和46.7%(14/30),差异无统计学意义,P>0.05。分析多因素对疗效的影响,差异均无统计学意义,P>0.05。NP组白细胞减少和局部静脉炎发生率高于GP组的发生率,P<0.05;GP组血小板减少、血红蛋白降低及脱发发生率高于NP组的发生率,P<0.05。初步研究结果提示,NP及GP方案均是治疗晚期NSCLC的有效方案,但毒副反应有所不同,应用时应加以注意。
The objective of this study was to compare the clinical efficacy and toxicity of chemotherapy with navelbine plus cisplatin （NP） or gemcitabine plus cisplatin（GP） in non-small cell lung cancer（NSCLC）. Sixty-two cases of NSCLC patients were treated with NP or GP for evaluating the clinical efficacy and toxicity. The overall response rates （ORR） in Group NP and Group GP were 46.9% （15/32） and 46.7 %（14/30）, respectively, P〉0.05. The main toxicity was hematological toxicity. The incidences of anemia, thrombocytopenia and alopeeie in Group GP were significantly higher than those in Group NP, P〈0.05. The incidences of leucopenia and partial phlebitis in Group NP were higher than that in Group GP, P-〈0.05. In conclusion, the efficacy is similar in Group GP and Group NP in the treatment of NSCLC, but there are differences in the toxicity between Group GP and Group NP.
出处
《中华肿瘤防治杂志》
CAS
2008年第17期1348-1350,共3页
Chinese Journal of Cancer Prevention and Treatment
关键词
癌
非小细胞肺/药物治疗
药物疗法
联合
治疗效果
carcinoma, non-small cell lung/durg therapy
durg therapy, combination
treatment outcome
